Thursday, August 28th, 2025
Stock Profile: ABEO
ABEO Logo

Abeona Therapeutics Inc. (ABEO)

Market: NASD | Currency: USD

Address: 6555 Carnegie Avenue

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Show more




📈 Abeona Therapeutics Inc. Historical Chart






📊 Statistics





💰 Dividend History


Year Annual Yield (%) Total Amount Current Yield (%) Ex Date Pay Date Particulars
2022 - $0.040000 - 2022-07-05 - Stock split
Total Amount for 2022: $0.040000


📅 Earnings & EPS History for Abeona Therapeutics Inc.


DateReported EPS
2025-11-13 (estimated upcoming)-
2025-08-14-0.47
2025-05-15-0.24
2025-03-20-0.32
2024-11-14-0.31
2024-08-12-0.44
2024-05-15-0.52
2024-03-18-0.48
2023-11-13-0.43
2023-08-08-0.5
2023-05-11-0.67
2022-11-14-1.48
2022-08-11-2.08
2022-05-13-3.5
2022-03-31-11.25
2021-11-15-3.52
2021-07-28-4
2021-05-17-4.25
2021-03-24-4.25
2020-11-09-2
2020-08-10-3.5
2020-05-06-4.11
2020-03-16-7.5
2019-11-12-8.75
2019-08-09-12.25




📰 Related News & Research


No related articles found for "abeona therapeutics".